Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 CBD Sol-Gel
- Development stage
- Preclinical
- Lead developer
- PreveCeutical Medical
- Modality
- Hydrogel Systems → Drug Delivery Systems, Small Molecules
- Administration
- Intranasal
01
Overview
COVID-19 CBD Sol-Gel is a nasal sol-gel formulation of cannabidiol (CBD) being developed by PreveCeutical Medical Inc. for the prevention and treatment of COVID-19 (SARS-CoV-2). The product utilizes a proprietary sol-gel technology that transitions from a liquid to a gel upon contact with the nasal mucosa, enabling sustained release of CBD for up to seven days. This delivery system is designed to provide direct action at the site of viral entry, leveraging CBD's anti-inflammatory properties and its potential to inhibit SARS-CoV-2 infection of nasal tissues while bypassing first-pass metabolism. The program is currently in the preclinical stage, with clinical trial planning underway in collaboration with the clinical research organization Veristat.
- Other names
- CBD Sol-Gelnasal CBD sol-gelcannabidiol sol-gel formulation
02
Targets
Mpro (3C-like proteinase of SARS-CoV-2)CB (Cannabinoid receptors)PPARG (Peroxisome proliferator-activated receptor gamma)ERN1 (Inositol-requiring enzyme 1 alpha)
Beyond the preview
Go deeper on COVID-19 CBD Sol-Gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 CBD Sol-Gel.